Premium
Peroxisome proliferator‐activated receptor‐ γ agonists as potential anti‐inflammatory agents in asthma and chronic obstructive pulmonary disease
Author(s) -
Spears M.,
McSharry C.,
Thomson N. C.
Publication year - 2006
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.2006.02604.x
Subject(s) - asthma , copd , medicine , inflammation , peroxisome proliferator activated receptor , immunology , pulmonary disease , pulmonary function testing , lung , respiratory disease , disease , receptor
Summary Inhaled corticosteroids are the most effective therapy for chronic persistent asthma and have a role in the treatment of chronic obstructive pulmonary disease (COPD). However, corticosteroids have reduced efficacy in some patients with asthma and fail to halt the progressive deterioration in lung function characteristic of COPD. Additional or alternative drug treatments to corticosteroids are required to improve control of inflammation in patients with therapy resistant airway disease. Peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) agonists have displayed potent anti‐inflammatory properties in experimental models of asthma and other airway diseases and as a result have the potential to become an additional treatment for asthma and COPD. We review the evidence from these experimental models and their applicability to asthma and COPD and the requirements for future clinical and experimental research.